Скачать или смотреть Oral Abstract Presentations | Kidney Cancer Research Summit 2025

This KCRS25 Oral Abstract session features in-depth research presentations spanning clinical trial results, biomarker discovery, tumor immunology, and integrative multi-omics in kidney cancer. Presenters share new data on targeted therapy combinations, immunotherapy outcomes, and molecular drivers of treatment resistance.

Moderators: Rana McKay (University of California, San Diego), Wesley Yip (City of Hope Comprehensive Cancer Center)

Combination Casdatifan plus Cabozantinib in Previously Treated Patients with Clear Cell RCC: Results from an Expansion Cohort of ARC-20 (NCT05536141) — Toni Choueiri (Dana-Farber Cancer Institute)

Pembrolizumab Plus Lenvatinib for Previously Untreated Advanced Non–Clear Cell RCC: 3-Year Follow-up of the Phase 2 KEYNOTE-B61 Study — Laurence Albiges (Institut Gustave Roussy)

CD163⁺ Tumor-Associated Macrophages and Clinical Outcomes to First-Line Nivolumab Therapy in Metastatic Clear Cell RCC: Insights from the HCRN GU16-260 Trial — Berkay Simsek (Brigham and Women's Hospital)

Integrative Clinical, Genomic, Transcriptomic, and Immunopathologic Characterization of Circulating KIM-1 in Metastatic RCC — Marc Machaalani (Dana-Farber Cancer Institute)

Lower Checkpoint Gene Expression is Associated with Primary Resistance to Nivolumab-Ipilimumab Combination in Advanced RCC — Rana McKay (University of California, San Diego)

Derepression of Human Endogenous Retroviruses in ccRCC: Implications for Immunotherapy — Qinqin Jiang (Dana-Farber Cancer Institute)